function. Modulation of pharmacokinetics and pharmacodynamics
of these drugs in cancer patients is therefore necessary
in order to improve tolerance.1 Cancer patients are
particularly liable for the development of renal abnormalities.
Interestingly, patients with renal abnormalities who have
undergone kidney transplantation are at high risk for malignancy.
Clinical symptoms of renal involvement are diverse
and harmful. Inspite of the recent advances in understanding
the mechanism of anticancer drug and nephrotoxicity, prevention
still relies on drug dosage decrease. Hence an active
screening of drugs for renal abnormalities for patients treated
with anticancer drugs is still a major field of research.